Grade ≥2 neurological toxicity was greater in the thalidomide-containing regimen, with sensory peripheral neuropathy being reported 2.9%, 3.6%, and 9.5% of patients in the quadruplet, triplet, and CTD cohorts, respectively. There was no statistically significant difference observed in rates of investigator-reported, all grade thromboembolic events between regimens.
Cardiac events including arrhythmias, heart failure, and hypertension occurred in fewer than 3% of patients.
“Induction therapy with KCRD, an outpatient delivered quadruplet regimen, was associated with deeper responses than either immunomodulatory triplet therapy, and was well tolerated,” said Pawlyn. “KCRD induction achieved a high rate of response in newly diagnosed transplant-eligible patients and the depth of response was consistent across all risk groups.”
Pawlyn C, et al. Quadruplet vs sequential triplet induction therapy for myeloma patients: results of the Myeloma XI study. Presented at: 22nd Annual European Hematology Association Congress; June 22-25, 2017; Madrid, Spain. Abstract S407.<<< More from the 2017 EHA Congress